SCHEMBL29435532

SCHEMBL29435532

CN(C(=O)OC(C)(C)C)c1cc(C(F)(F)F)cnc1N=[N+]=[N-]

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.35
KDM4E B2RXH2 2/20 0.35
HPGD P15428 1/20 0.35
MAPT P10636 1/20 0.34
CACNA1G O43497 1/20 0.34
CACNA1B Q00975 1/20 0.34
CACNA1C Q13936 1/20 0.34
MAPK1 P28482 1/20 0.34
LIPE Q05469 5/20 0.34
POLQ O75417 1/20 0.33
PLAU P00749 1/20 0.32
AGBL2 Q5U5Z8 1/20 0.32
KMT2A Q03164 3/20 0.32
MEN1 O00255 2/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
GAA P10253 1/20 0.32
CYP2C19 P33261 1/20 0.32
RXRA P19793 1/20 0.31
NR1H2 P55055 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22583575 0.84 AGBL2 (0.38) ALDH1A1KDM4EHPGDMAPTMAPK1
SCHEMBL22583230 0.82 ALDH1A1 (0.37) ALDH1A1KDM4EHPGDMAPTCACNA1G
SCHEMBL29435707 0.80 CACNA1G (0.34) ALDH1A1CACNA1GCACNA1BCACNA1CLIPE
SCHEMBL22583020 0.78 ALDH1A1 (0.38) ALDH1A1KDM4EHPGDMAPTCACNA1G
SCHEMBL29435611 0.78 ALDH1A1 (0.43) ALDH1A1KDM4EHPGDMAPTCACNA1G
SCHEMBL30400756 0.73 CACNA1G (0.32) ALDH1A1CACNA1GCACNA1BCACNA1CRXRA
SCHEMBL22583484 0.72 ALDH1A1 (0.39) ALDH1A1KDM4EHPGDMAPTCACNA1G
SCHEMBL29601868 0.72 ALDH1A1 (0.39) ALDH1A1KDM4EHPGDMAPTCACNA1G
SCHEMBL29435518 0.72 ALDH1A1 (0.32) ALDH1A1
SCHEMBL22583033 0.70 KMT2A (0.37) ALDH1A1KDM4EHPGDMAPTCACNA1G

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250276967-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES SIGNAL PHARMACEUTICALS, LLC 2025-09-04 US disclosed
US-12338235-B2 Heterocyclic compounds and their use for treatment of helminthic infections and diseases CELGENE CORPORATION (US) 2025-06-24 US disclosed
US-11505548-B2 Heterocyclic compounds and their use for treatment of helminthic infections and diseases CELGENE CORPORATION (US) 2022-11-22 US disclosed
EP-3959207-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES Celgene Corporation (US) 2022-03-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250276967-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES CYP8B1, HAX1, HRH4 ALDH1A1 1513/4885KDM4E 3831/4885HPGD 110/4885
US-11505548-B2 Heterocyclic compounds and their use for treatment of helminthic infections and diseases CYP8B1, HAX1, HRH4 ALDH1A1 1513/4885KDM4E 3831/4885HPGD 110/4885
US-12338235-B2 Heterocyclic compounds and their use for treatment of helminthic infections and diseases CYP8B1, HAX1, HRH4 ALDH1A1 1513/4885KDM4E 3831/4885HPGD 110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.